|Awarded On||August 16, 2017|
|Title||An Unexpected Oncometabolic Axis: Exposing Novel Regulators of Cardiac Remodeling in Leukemia|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Heinrich Taegtmeyer|
Acute myeloid leukemia (AML) affects 20,000 Americans annually and is the most common cancer in children. Improved treatments have increased patient survival, but despite these efforts survivors have a five-fold higher risk for developing heart failure. Recent advances in clinical and basic research studies have found that deteriorating cardiovascular events occur in survivors independent of the type of cancer treatment. This underscores the need for innovative therapeutic strategies to target leukemia cells and to ultimately protect the heart. Specific metabolic activities provide benefits to cancer cells and drive tumor growth. Two genes called IDH1 and IDH2 are mutated in 20% of AML cases...